Share this:
A novel single-cycle adenovirus vaccine platform developed by Mayo Clinic will be used to target multiple infectious diseases and cancer indications, beginning with a phase 1 clinical study using the platform as a vaccine for COVID-19.
Developed to enhance the expression of target antigens, the single-cycle adenovirus platform is under investigation for its ability to amplify immune responses. In contrast to replication-defective vaccines, the single-cycle vector amplifies immune response potential based on preclinical trials.
“The single-cycle adenovirus vaccine engine amplifies SARS-CoV-2 spike antigen production nearly 100-fold when compared to matched replication-defective adenoviruses,” says Michael Barry, Ph.D., the director of Mayo Clinic's Vector and Vaccine Engineering Laboratory and co-developer of the platform. “Single-cycle is particularly potent as a nasal vaccine, fighting SARS at its site of entry.”
The single-cycle adenovirus vaccine platform was licensed to Tetherex Pharmaceuticals, Inc., a privately-held biopharmaceutical company, which announced the start of the Phase 1 trial.
Read more about this adenovirus platform and Dr. Barry’s work here.
_______________________________________________
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about: Tracking COVID-19 and COVID-19 trends.
